Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

At the annual meeting of the European Society of Cardiology, being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to | The latest ...

Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis (PBC), clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and ...

Plexium has raised $60.1 million, providing an infusion of cash for the r | Plexium has raised $60.1 million, providing an infusion of cash to the recently slimmed-down protein degrader specialist ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

A phase 1 study has linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs, hindering the biotech’s positioning in early symptomatic Alzheimer’s ...

Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...